Immuno-oncology Drugs Market

Immunotherapy is treatment that uses a certain part of a person?s immune system to fight diseases which is done by stimulating one?s own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body?s immune system in a very general way and others help train the immune system to attack cancer cells specifically.

Immuno-oncology Drugs Market contains market size and forecasts of Immuno-oncology Drugs in global, including the following market information:

Global Immuno-oncology Drugs Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Immuno-oncology Drugs Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Immuno-oncology Drugs companies in 2021 (%)

The global Immuno-oncology Drugs market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Immune Checkpoint Inhibitors Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Immuno-oncology Drugs include Amgen, Inc, AstraZeneca, Plc, Bristol-Myers Squibb, Celgene Corporation, Eli Lilly and Company, Merck & Co., Hoffmann-La Roche AG, Johnson & Johnson and Novartis International AG, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Immuno-oncology Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Immuno-oncology Drugs Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Immuno-oncology Drugs Market Segment Percentages, by Type, 2021 (%)

• Immune Checkpoint Inhibitors
• Immune System Modulators
• Cancer Vaccines
• Oncolytic Virus
• Others

Global Immuno-oncology Drugs Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Immuno-oncology Drugs Market Segment Percentages, by Application, 2021 (%)

• Hospitals
• Clinics
• Ambulatory Surgical Centers

Global Immuno-oncology Drugs Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Immuno-oncology Drugs Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Immuno-oncology Drugs revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Immuno-oncology Drugs revenues share in global market, 2021 (%)
• Key companies Immuno-oncology Drugs sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Immuno-oncology Drugs sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Amgen, Inc
• AstraZeneca, Plc
• Bristol-Myers Squibb
• Celgene Corporation
• Eli Lilly and Company
• Merck & Co.
• Hoffmann-La Roche AG
• Johnson & Johnson
• Novartis International AG
• AbbVie, Inc.
• Pfizer Inc.
• Sanofi S.A.
• EMD Serono, Inc.
• Gilead Sciences Inc.
• Prometheus Therapeutics & Diagnostics
• Aduro BioTech
• Galena Biopharma
• Bavarian Nordic
• Celldex Therapeutics
• ImmunoCellular Therapeutics
• Incyte
• Dendreon Corporation
• Agilent Technologies Inc.
• Agenus Inc.
• Enzo Biochem, Inc.
• Lonza Group
• Bio-Rad Laboratories, Inc.
• Avantor, Inc.
• Spring Bank Pharmaceuticals, Inc.
• Ferring Pharmaceuticals